Exemestane in the prevention setting

Therapeutic Advances in Medical Oncology

Volumn 4, Issue 3, 2012, Pages 107-112

  Litton, Jennifer Keating ^a   Arun, Banu K ^a   Bevers, Therese B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

aromatase inhibitors; breast cancer; exemestane; prevention

Indexed keywords

EXEMESTANE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTHRALGIA; ARTHRITIS; BODY WEIGHT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; DEPRESSION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIAL DISEASE; FATIGUE; FRACTURE; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; ISCHEMIC HEART DISEASE; MONOTHERAPY; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; OSTEOPOROSIS; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84864439172     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012438214     Document Type: Review

References (35)

1. ATAC (2008) The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45–53.
2. Beresford M. Tumur I. Chakrabarti J. Barden J. Rao N. Makris A. (2010) A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin Oncol (R Coll Radiol) 23: 209–215.
3. Casper R. (2007) Aromatase inhibitors in ovarian stimulation. J Steroid Biochem Mol Biol 106(1-5): 71–75.
4. Coleman R.E. Banks L.M. Girgis S.I. Kilburn L.S. Vrdoljak E. Fox J. et al. (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8: 119–127.
5. Coombes R.C. Kilburn L.S. Snowdon C.F. Paridaens R. Coleman R.E. Jones S.E. et al. (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369: 559–570.
6. Dowsett M. Stein R.C. Coombes R.C. (1992) Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol 43: 155–159.
7. Ellis M.J. Suman V.J. Hoog J. Lin L. Snider J. Prat A. et al. (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype ACOSOG Z1031. J Clin Oncol 29: 2342–2349.
8. Endogenous Hormones and Breast Cancer Collaborative Group (2011) Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 105: 709–722.
9. Evans T.R.J. Di Salle E. Ornati G. Lassus M. Benedetti M.S. Pianezzola E. et al. (1992) Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 52: 5933–5939.
10. Fallowfield L.J. Bliss J.M. Porter L.S. Price M.H. Snowdon C.F. Jones S.E. et al. (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24: 910–917.
11. Fisher B. Costantino J.P. Wickerham D.L. Cecchini R.S. Cronin W.M. Robidoux A. et al. (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 97: 1652–1662.
12. Fisher B. Dignam J. Wolmark N. Wickerham D.L. Fisher E.R. Mamounas E. et al. (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353: 1993–2000.
13. Francini G. Petrioli R. Montagnani A. Cadirni A. Campagna S. Francini E. et al. (2006) Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 95: 153–158.
14. Goss P.E. Ingle J.N. Ales-Martinez J. Cheung A.M. Chlebowski R.T. Wactawski-Wende J. et al. (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364: 2381–2391.
15. Grodin J.M. Siiteri P.K. Macdonald P.C. (1973) Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36: 207–214.
16. Hadji P. Asmar L. van Nes J. Menschik T. Hasenburg A. Kuck J. et al. (2011) The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J Cancer Res Clin Oncol 137: 1015–1025.
17. Johannessen D.C. Engan T. Di Salle E. Zurlo M.G. Paolini J. Ornati G. et al. (1997) Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 3: 1101–1108.
18. Johnston S.R.D. Dowsett M. (2003) Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3: 821–831.
19. Jones S. Vogel C. Arkhipov A. Fehrenbacher L. Eisenberg P. Cooper B. et al. (1999) Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol 17: 3418–3425.
20. Kaufmann M. Bajetta E. Dirix L.Y. Fein L.E. Jones S. Zilembo N. et al. (2000) Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. Clin Breast Cancer 1 (0): S15–S18.
21. Kvinnsland S. Anker G. Dirix L.Y. Bonneterre J. Prove A.M. Wilking N. et al. (2000) High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 36: 976–982.
22. Lustberg M. Povoski S. Zhao W. Ziegler R. Sugimoto Y. Ruppert A. et al. (2011) Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer 11: 221–227.
23. Paridaens R. Dirix L. Beex L. Nooij M. Cufer T. Lohrisch C. et al. (2000) Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. Clin Breast Cancer 1 (0): S19–S21.
24. Pasqualini J.R. Chetrite G. Blacker C. Feinstein M.C. Delalonde L. Talbi M. et al. (1996) Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81: 1460–1464.
25. Ropka M.E. Keim J. Philbrick J.T. (2010) Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 28: 3090-3095.
26. Santen R. Brodie H. Simpson E. Siiteri P. Brodie A. (2009) History of Aromatase: Saga of an important biological mediator and therapeutic target. Endocrine Rev 30: 343–375.
27. Schilder C.M.T. Seynaeve C. Linn S.C. Boogerd W. Beex L.V.A.M. Gundy C.M. et al. (2011) Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. Psycho-Oncology, DOI: 10.1002/pon.192810.1002/pon.1928.
28. Schwarzel W.C. Kruggel W.G. Brodie H.J. (1973) Studies on the mechanism of estrogen biosynthesis. VIII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 92: 866–880.
29. Simpson E.R. Bulun S.E. Nichols J.E. Zhao Y. (1996) Estrogen biosynthesis in adipose tissue: regulation by paracrine and autocrine mechanisms. J Endocrinol 150(3 Suppl.): S51–S57.
30. Szymczak J. Milewicz A. Thijssen J.H.H. Blankenstein M.A. Daroszewski J. (1998) Concentration of sex steroids in adipose tissue after menopause. Steroids 63: 319–321.
31. van de Velde C.J.H. Rea D. Seynaeve C. Putter H. Hasenburg A. Vannetzel J.-M. et al. (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377: 321–331.
32. Visvanathan K. Chlebowski R.T. Hurley P. Col N.F. Ropka M. Collyar D. et al. (2009) American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27: 3235–3258.
33. Vogel V.G. Costantino J.P. Wickerham D.L. Cronin W.M. Cecchini R.S. Atkins J.N. et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295: 2727–2741.
34. Vogel V.G. Costantino J.P. Wickerham D.L. Cronin W.M. Cecchini R.S. Atkins J.N. et al. (2010) Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prevention Res 3: 696–706.
35. Zilembo N. Noberasco C. Bajetta E. Martinetti A. Mariani L. Orefice S. et al. (1995) Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 72: 1007–1012.